<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400905</url>
  </required_header>
  <id_info>
    <org_study_id>CID-100</org_study_id>
    <nct_id>NCT02400905</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System</brief_title>
  <acronym>MIMICS-2</acronym>
  <official_title>MIMICS-2: Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System in the Femoropopliteal Arteries of Patients With Symptomatic Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veryan Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinLogix. LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale Cardiovascular Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Veryan Medical Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that the BioMimics 3D Stent System meets the performance goals defined by VIVA
      Physicians, Inc. for the safety and effectiveness of Nitinol stents used in the treatment of
      symptomatic disease of the femoropopliteal artery. It is a prospective, single-arm,
      multicenter clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BioMimics 3D stent is intended to improve luminal diameter in the treatment of
      symptomatic de-novo, obstructive or occlusive lesions in native femoropopliteal arteries with
      reference vessel diameters ranging from 4.0 - 6.0 mm. Subjects with symptomatic
      atherosclerotic disease of the femoropopliteal artery who comply with all study eligibility
      criteria may be considered for enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 29, 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">November 8, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint (composite of major adverse events (MAE)</measure>
    <time_frame>30 days</time_frame>
    <description>A composite of major adverse events (MAE) comprising death, any major amputation performed on the target limb or clinically-driven target lesion revascularization (TLR) through 30 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint (Primary stent patency rate)</measure>
    <time_frame>12 months</time_frame>
    <description>Primary stent patency rate at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary safety (overall MAE rate at 30 days)</measure>
    <time_frame>30 Days</time_frame>
    <description>Contribution of individual MAE rates for death, major amputation performed on the target limb and clinically-driven target lesion revascularization to the overall MAE rate at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term safety (Overall MAE rate at Month 12)</measure>
    <time_frame>12 months</time_frame>
    <description>Overall MAE rate at Month 12 and contribution of individual event rates to the overall MAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term Safety (Overall rate and incidence of type of serious adverse events)</measure>
    <time_frame>36 Months</time_frame>
    <description>Overall rate and incidence of type of serious adverse events from Day 0 through completion of Study follow-up at Month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success ( percentage of treated lesions in which a final result of ≤50% residual diameter stenosis (in-stent) was achieved at index procedure)</measure>
    <time_frame>Procedural</time_frame>
    <description>Technical success reported by the core lab as the</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary stent patency</measure>
    <time_frame>Months 12 &amp; 24</time_frame>
    <description>Determined at Months-12 and 24 using values of: PSVR &gt;2.0, &gt;2.4; &gt;2.5; and &gt;3.5, each to indicate loss of patency on duplex ultrasound or where angiography reveals &gt;50% diameter stenosis or where the subject undergoes clinically-driven TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome (Rutherford Clinical Category)</measure>
    <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
    <description>Comparison of Rutherford Clinical Category measured at Baseline, Day 30, Months 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome (Six-Minute Walk Test)</measure>
    <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
    <description>Comparison of measured at Baseline, Day 30, Months 12 and 24 (subgroup of US investigational sites only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome (ankle brachial index (ABI) measurement)</measure>
    <time_frame>Day 30, Months 12 &amp; 24</time_frame>
    <description>Comparison of the ankle brachial index (ABI) measurement at Baseline, within 30 days after index procedure, then at Months 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome (Walking Impairment Questionnaire)</measure>
    <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
    <description>Comparison of the Walking Impairment Questionnaire at Baseline, within 30 days after index procedure, then at Months 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent integrity (measured as freedom from stent fracture)</measure>
    <time_frame>Months 12, 24 &amp; 36</time_frame>
    <description>Stent integrity measured as freedom from stent fracture.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>BioMimics 3D Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioMimics 3D Stent System</intervention_name>
    <description>Femoropopliteal stenting</description>
    <arm_group_label>BioMimics 3D Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic peripheral arterial disease (PAD) of the lower extremities requiring
             intervention to relieve de novo obstruction or occlusion of the native femoropopliteal
             artery.

          -  PAD classified as Rutherford clinical category 2, 3 or 4.

          -  Resting ankle-brachial index (ABI) of ≤0.90 (or ≤0.75 after exercise of the target
             limb) or angiographic or DUS evidence of &gt;/= 60%.

          -  Single or multiple stenotic or occlusive lesions within the native femoropopliteal
             artery (&quot;target lesions&quot;) that can be crossed with a guidewire and fully dilated.

          -  Single or multiple target lesions must be covered by a single stent or two overlapping
             stents.

          -  Target lesion(s) eligible for treatment at least 1 cm distal to the origin of the deep
             femoral artery and at least 3 cm above the bottom of the femur.

          -  Target lesion(s) reference vessel diameter is between 4.0 mm and 6.0 mm.

          -  Single or multiple target lesions measure ≥40 mm to ≤140 mm in overall length, with
             ≥60% diameter stenosis by operator's visual estimate.

          -  Patent popliteal artery (no stenosis ≥50%) distal to the treated segment.

          -  At least one patent infrapopliteal vessel (&lt;50% stenosis) with run-off to the ankle.

        Exclusion Criteria:

          -  Iliac stent in target limb that has required re-intervention within 12 months prior to
             index.

          -  Target vessel that has been treated with bypass surgery.

          -  PAD classified as Rutherford clinical category 0, 1, 5 or 6.

          -  Known coagulopathy or has bleeding diatheses, thrombocytopenia with platelet count
             less than 100,000/microliter or INR &gt;1.8.

          -  Stroke diagnosis within 3 months prior to enrollment.

          -  History of unstable angina or myocardial infarction within 60 days prior to
             enrollment.

          -  Thrombolysis within 72 hours prior to the index procedure.

          -  Acute or chronic renal disease (e.g., as measured by a serum creatinine of &gt;2.5 mg/dL
             or &gt;220 umol/L), or on peritoneal or hemodialysis.

          -  Significant disease or obstruction (≥50%) of the inflow tract that has not been
             successfully treated at the time of the index procedure (success measured as ≤30%
             residual stenosis, without complication).

          -  No patent (≥50% stenosis) outflow vessel providing run-off to the ankle.

          -  Target lesion(s) requires percutaneous interventional treatment, beyond standard
             balloon angioplasty alone, prior to placement of the study stent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy M. Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Heart Institute / Abbott Northwestern Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Zeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herz-Zentrum University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masato Nakamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toho University Ohashi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brookwood Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of Mobile</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Heart Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradenton Cardiology Center</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediQuest Research Group/ Munroe Regional Medical Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Vascular</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF St. Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings Daughters Medical Center</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endovascular Technologies / Grace Research</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Outpatient Vascular Institute</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital &amp; Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Vascular Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Heart &amp; Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Heart &amp; Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Harrisburg</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berks Cardiologists</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Central Heart</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kore Cardiovascular Research</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Specialist of TX / North Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grace Research</name>
      <address>
        <city>Huntsville</city>
        <state>Texas</state>
        <zip>77340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Research Institute/Guadalupe Regional Medical Center</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of East Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinen-Hospital</name>
      <address>
        <city>Arnsberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Herzzentrum Freiburg-Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonissenkrankenhaus Flensburg</name>
      <address>
        <city>Flensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westküstenklinikum Heide</name>
      <address>
        <city>Heide</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AoR Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bonifatius Hospital</name>
      <address>
        <city>Lingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasukabe Chuo General Hospital</name>
      <address>
        <city>Kasukabe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morinomiya Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omihachiman Community Medical Center</name>
      <address>
        <city>Shiga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD</keyword>
  <keyword>PVD</keyword>
  <keyword>SFA stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

